EVOLUT Low-Risk Trial data: "We see what we want to see!"
Pradeep NarayanPublished in: Indian journal of thoracic and cardiovascular surgery (2024)
In the 4-year update of the EVOLUT Low-Risk Trial (NCT02701283), the authors highlight a non-significant improvement in the primary endpoint and a statistically significant, yet clinically irrelevant, enhancement in hemodynamics with transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR). Overlooking the concurrent surgical procedures in SAVR patients, mortality rates remain similar at 4 years. Unaddressed is the substantial increase in permanent pacemaker implantations with TAVR and the fate of patients with paravalvular leaks.
Keyphrases
- aortic stenosis
- transcatheter aortic valve replacement
- transcatheter aortic valve implantation
- aortic valve replacement
- ejection fraction
- aortic valve
- end stage renal disease
- study protocol
- phase iii
- chronic kidney disease
- left ventricular
- clinical trial
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- randomized controlled trial
- risk factors
- machine learning
- patient reported
- electronic health record
- artificial intelligence
- atrial fibrillation